SecBot SecBot
8-K ·Filed Aug 13, 2026

FOCL

EDAP TMS SA
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001171843-26-005498
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Strong HIFU revenue and system sales growth are overshadowed by the $40M dilutive offering announced alongside this earnings release. The net loss excluding the warrant charge (~$8.9M) is still meaningfully worse than consensus EPS of -$0.20. With shareholders' equity now negative and a dilutive capital raise underway, near-term stock pressure likely outweighs the positive commercial momentum. Monitor post-offering share structure and cash runway.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.76
T+0 close · Aug 13, 2026 · via day close
Latest settled
−26.05%
T+60 · $3.52
Vs SPY
−23.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $4.76entry
  2. T+1 · 3mo ago −8.40%α −7.93% · $4.36
  3. T+5 · 3mo ago −13.24%α −11.87% · $4.13
  4. T+20 · 2mo ago −13.66%α −11.66% · $4.11
  5. T+60 · 8d ago −26.05%α −23.00% · $3.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

FocalTherics (FOCL) reported strong Q2 2026 HIFU continuing operations revenue of $13.2M (+39% YoY), with 13 Focal One system sales (+44% YoY) and 47% US procedure growth. However, the net loss widened to $14.4M ($0.38 loss per share) from $6.4M ($0.17 loss) due to a $5.5M EIB warrant valuation charge, and the company announced a $40M dilutive public offering. Management reiterated full-year 2026 revenue guidance of $50-54M (34-45% YoY growth).

Key Financial Metrics

EPS
−$0.38
est −$0.20 · -90.0%
Revenue
$13.2M
est $15.1M · -12.6% · +39.0% YoY
Rating
miss
Guidance
$50.0M-$54.0M
maintained
Free Cash Flow
-$8.7M
Gross Margin
55.6%

Key Facts

  • HIFU continuing operations revenue rose 39% YoY to $13.2M (Q2 2026 vs Q2 2025: $9.5M); consensus was $15.1M.
  • 13 Focal One capital system sales in Q2 2026 vs 9 in prior year period, including 2 lease conversions (+44% YoY).
  • Gross margin improved to 55.6% from 51.1% YoY.
  • Net loss from continuing operations was $14.4M ($0.38/share) vs $6.4M ($0.17/share) in Q2 2025, the increase was primarily due to a $5.5M loss from change in fair value of warrant liability.
  • Adjusted net loss from continuing operations (excluding the $5.5M warrant impact) was approximately $8.9M ($0.24/share), which is near consensus EPS of -$0.20.
  • Management reiterated 2026 full-year guidance for continuing operations: total revenue of $50.0-54.0M (34-45% YoY growth).
  • Announced an underwritten public offering for $40M of gross proceeds, expected to close August 14, 2026.
  • Completed corporate name change to FocalTherics and reclassified ESWL/Distribution segments as discontinued operations.
  • Cash and cash equivalents of $21.5M as of June 30, 2026.
  • Shareholders' equity was negative ($3.2M) as of June 30, 2026 (vs positive $19.4M at Dec 31, 2025), driven by a large warrant liability.

Financial Impact

Revenue up 39% YoY to $13.2M; net loss widened to $14.4M largely due to $5.5M non-cash warrant revaluation. $40M dilutive offering to close Aug 14.

revenueepsdilutionshareholders' equitywarrant liability

Risk Factors

  • $40M dilutive public offering will increase share count significantly, potentially diluting existing shareholders by >20% given current market cap of ~$178M.
  • Negative shareholders' equity of -$3.2M and large warrant liability ($6.9M related to Tranche A and B borrowings) indicate balance sheet strain.
  • Operating cash flow remained negative at -$6.7M for H1 2026, suggesting ongoing reliance on external capital.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
73% bullish (11 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-005498
Document: f8k_081326.htm0001171843-26-005498
Document: 0001171843-26-005498-index-headers.html0001171843-26-005498
Document: 0001171843-26-005498-index.html0001171843-26-005498
Document: 0001171843-26-005498.txt0001171843-26-005498
8-K Data (Synthetic)0001171843-26-005498

Track record

9 reports on FOCL

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.05% at T+60 after the Aug 14, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $3.32 Now $3.17 −4.52% settles Feb 4
  2. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $4.15 Now $3.17 −23.61% settles Jan 21
  3. Oct 19, 202628d ago SC 13G Neutral 3/10 Entry $4.07 Now $3.17 −22.11% settles Jan 14
  4. Aug 19, 202612w ago 8-K Bearish 6/10 Entry $4.36 to $3.41 Now $3.17 +27.29% ▲ +21.79% +20.24% vs SPY
  5. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $4.76 to $3.52 Now $3.17 +33.40% ▲ +26.05% +23.00% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 Viewing Entry $4.76 to $3.52 Now $3.17 −33.40% ▼ −26.05% −23.00% vs SPY
  7. Aug 11, 202613w ago Press Release Mixed 6/10 Entry $4.75 to $4.25 Now $3.17 −33.26% ▼ −10.53% −5.41% vs SPY
  8. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $4.75 to $4.25 Now $3.17 −33.26% ▼ −10.53% −5.41% vs SPY
  9. Jul 30, 202615w ago Press Release Neutral 1/10 Entry $6.12 to $4.23 Now $3.17 −48.20% ▼ −30.88% −33.34% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (9h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026